

## Synergistic Suppression Effect on Tumor Growth of Acute Myeloid Leukemia by Combining Cytarabine with an Engineered Oncolytic Vaccinia Virus [Retraction]

Peng J, Wang S, Fan W, et al. Onco Targets Ther. 2018;11:6887-6900.

At the authors request, the Editor and Publisher of *OncoTargets and Therapy* wish to retract the published article. The authors requested to replace western blot images in Figure 4, where images for Figure 4, THP-1, CyclinD1 and THP-1, CDK2 appeared to have been duplicated. Further analysis found evidence for the manipulation of western blot images in Figure 3. Specifically,

• Images for Figure 3B, panels KG-1; HL-60; K562, p53/p100 all appear to have been duplicated and enhanced to give the appearance of being distinct western blot bands.

The authors provided some original western blot data, but it was not satisfactory and was unable to adequately verify the reported findings. The authors requested to retract the article and the Editor agreed with this.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as "Retracted".

## OncoTargets and Therapy

## **Dove**press

## Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <a href="https://www.dovepress.com/testimonials.php">https://www.dovepress.com/testimonials.php</a> to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/oncotargets-and-therapy-journal

https://doi.org/10.2147/OTT.S392085